NEW YORK (GenomeWeb News) - Caprion Pharmaceuticals has withdrawn its initial public offering due to “adverse market conditions,” the company said today.
Drug makers use the company’s CellCarta product, a proteomics technology, to profile proteins in solid tissues and plasma for disease-target identification and predictive medicine.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.